Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Tim Luke who wrote (29639)	12/17/1998 8:35:00 AM
From: Archie Goodwin	Respond to of 119973

(COMTEX) B: AASTROM BIOSCIENCES ANNOUNCES CE MARK APPROVAL FOR STEM C B: AASTROM BIOSCIENCES ANNOUNCES CE MARK APPROVAL FOR STEM CELL THERAPY KIT REGULATORY APPROVALS NOW IN PLACE TO PERMIT EUROPEAN MARKET Introduction of the AastromReplicell(TM) System ANN ARBOR, Mich., Dec. 17 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), today announced that it has obtained approval to affix the CE Mark to the AastromReplicell(TM) Cell Production System (System) liquid products of the SC-I Therapy Kit to produce bone marrow cells for use in stem cell therapy. This announcement follows an earlier approval received by Aastrom to affix the CE Mark to the AastromReplicell(TM) System instrumentation platform, and now allows marketing activities to begin in the European Community. The AastromReplicell(TM) System instrumentation platform is designed to operate different therapy-specific kits including the SC-I Therapy Kit. "The CE Mark approach to regulatory approval provided to the AastromReplicell(TM) System, may set a standard for cell therapy applications in Europe, and we believe will assist in more general therapeutic uses of ex vivo expanded cells. The therapy-specific kit approach not only enables hospitals to have access to needed cells, but also provides both a standardized mechanism and increased reliability for different treatment centers to carry out therapeutic cell (COMTEX) B: AASTROM BIOSCIENCES ANNOUNCES CE MARK APPROVAL FOR STEM C B: AASTROM BIOSCIENCES ANNOUNCES CE MARK APPROVAL FOR STEM CELL THERAPY KIT REGULATORY APPROVALS NOW IN PLACE TO PERMIT EUROPEAN MARKET Regards A.G.